Generalized myasthenia gravis is an autoimmune neuromuscular junction disorder with fluctuating weakness that extends beyond ocular muscles to bulbar, axial, limb, and potentially respiratory muscles. Disease severity can vary and may lead to myasthenic crisis requiring emergency care. It is often managed with symptomatic and immunosuppressive therapy.
The IRA's price controls could raise long-term drug prices by 21% for the first 25 selected drugs, while Medicare's $2,000 out-of-pocket cap encourages plans to favor IV over equally effective subcutaneous versions.
Regeneron announced FDA and EMA review acceptance for cemdisiran in generalized myasthenia gravis and FDA priority review acceptance for garetosmab in fibrodysplasia ossificans progressiva. The garetosmab BLA is supported by Phase 3 OPTIMA trial data showing 94% and 90% reductions in new bone lesions.
The FDA expanded efgartigimod approval to all adult generalized myasthenia gravis serotypes. Phase 3 ADAPT SERON met its primary endpoint and showed no new safety signals.
argenx reported $1.3B in Q1 2026 global product net sales (63% YoY growth). The FDA PDUFA target date for seronegative gMG is May 10, 2026. Positive ADAPT OCULUS results support an oMG label expansion. Pipeline milestones include myositis readout in Q3 2026 and MMN readout in Q4 2026.
Three FcRn inhibitors are approved for generalized myasthenia gravis, with a head-to-head trial of efgartigimod and nipocalimab underway. Emerging therapies including telitacicept, gefurulimab, and CAR-T cell therapy (KYV-101) show promise, while Immunovant's batoclimab failed TED trials.
January and March 2026 drug pipeline updates included Phase 3 results, Fast Track designations and Priority Review decisions across multiple disease areas. Mavacamten, teplizumab-mzwv, anifrolumab, AXS-05, gedatolisib and AFTX-201 were among the programs with notable milestones.
Regeneron said the Phase 3 NIMBLE trial of cemdisiran in generalized myasthenia gravis met primary and key secondary endpoints at week 24. The company said a U.S. regulatory application has been submitted and EU filings are planned for 2026.
Kyverna Therapeutics reports positive long-term follow-up results for its CAR-T therapy miv-cel in generalized myasthenia gravis, with plans to submit a biologics license application in the first half of 2026. The company has $279.3 million in cash providing runway into 2028 to fund launch and Phase 3 trials.
Johnson & Johnson reported strong Q4 2025 earnings with $2.46 adjusted EPS and $24.56 billion in sales, beating estimates. The company faces over 67,000 active talc lawsuits following recent trial losses while projecting 2026 sales of $100-101 billion and maintaining a robust pipeline with recent FDA approvals and breakthrough designations.
Amgen received FDA and European Commission approval for Uplizna to treat generalized myasthenia gravis in adults who are anti-AChR or anti-MuSK antibody positive, offering twice-yearly maintenance dosing after initial loading doses.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07714798 |
Universal STAR-T Cell Injection in Generalized Myasthenia Gravis |
NOT_YET_RECRUITING | PHASE1 |
| NCT07622342 |
A Phase II Study of SHR-2173 Injection in Patients With Myasthenia Gravis |
NOT_YET_RECRUITING | PHASE2 |
| NCT07596784 |
Efficacy and Safety of Ravulizumab in Chinese Adults Participants With Generalized Myasthenia Gravis (gMG) |
NOT_YET_RECRUITING | PHASE3 |
| NCT07570589 |
Monitor the Evolution of Myasthenia Gravis Symptoms in Real-life in Patients With Anti-AChR and Anti-MUSK Generalised Myasthenia Gravis in Therapy With RYSTIGGO® (Rozanolixizumab) |
RECRUITING | |
| NCT07556120 |
Efficacy and Safety of HN2301 in Patients With Generalized Myasthenia Gravis (MG) |
NOT_YET_RECRUITING | PHASE1 |
| NCT07294170 |
ADAPT Forward - Master Protocol of a Platform Study to Evaluate the Safety and Efficacy of Multiple Regimens in Participants With Myasthenia Gravis |
RECRUITING | |
| NCT07284420 |
ADAPT Forward 1 - ISA1 - a Study to Evaluate Empasiprubart IV as add-on Therapy to Efgartigimod IV in Participants With AChR-Ab Seropositive Generalized Myasthenia Gravis With a Partial Clinical Response to Efgartigimod |
RECRUITING | PHASE2 |
| NCT07221838 |
A Study to Investigate OCS Tapering in Adult Participants With Generalized Myasthenia Gravis Treated With Ravulizumab |
RECRUITING | PHASE4 |
| NCT07215650 |
Clinical Study of Cizutamig in Generalized Myasthenia Gravis (gMG) |
RECRUITING | PHASE1 |
| NCT07039916 |
Study to Assess the Efficacy and Safety of IMVT-1402 in Participants With Mild to Severe Generalized Myasthenia Gravis |
RECRUITING | PHASE3 |
